Co-Authors
This is a "connection" page, showing publications co-authored by Katie Doores and Michael Malim.
Connection Strength
1.388
-
Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. Immunity. 2021 06 08; 54(6):1276-1289.e6.
Score: 0.234
-
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020 12; 5(12):1598-1607.
Score: 0.227
-
Translational Research in the Time of COVID-19-Dissolving Boundaries. PLoS Pathog. 2020 09; 16(9):e1008898.
Score: 0.226
-
Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2 infection early in the pandemic and the role of unidentified cases in transmission. Clin Microbiol Infect. 2022 Jan; 28(1):93-100.
Score: 0.060
-
The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. Lancet Rheumatol. 2021 Sep; 3(9):e627-e637.
Score: 0.060
-
Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: a single-centre laboratory evaluation study. Lancet Microbe. 2021 Sep; 2(9):e461-e471.
Score: 0.060
-
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia. Br J Haematol. 2021 09; 194(6):999-1006.
Score: 0.059
-
SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity. Sci Adv. 2021 05; 7(22).
Score: 0.059
-
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. Leukemia. 2021 12; 35(12):3573-3577.
Score: 0.059
-
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021 06; 22(6):765-778.
Score: 0.059
-
Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: Results from a pilot service implemented during the first pandemic wave. PLoS One. 2021; 16(4):e0249791.
Score: 0.059
-
Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England. J Infect. 2020 12; 81(6):931-936.
Score: 0.057
-
Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. PLoS Pathog. 2020 09; 16(9):e1008817.
Score: 0.057
-
Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. Nat Med. 2020 11; 26(11):1701-1707.
Score: 0.056
-
Real-world evaluation of a novel technology for quantitative simultaneous antibody detection against multiple SARS-CoV-2 antigens in a cohort of patients presenting with COVID-19 syndrome. Analyst. 2020 Aug 21; 145(16):5638-5646.
Score: 0.056